Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Everett E. Vokes, N. Ready, E. Felip, L. Horn, M. A. Burgio, S. J. Antonia, O. Arén Frontera, S. Gettinger, E. Holgado, D. Spigel, D. Waterhouse, M. Domine, M. Garassino, L. Q.M. Chow, G. Blumenschein, F. Barlesi, B. Coudert, J. Gainor, O. Arrieta, J. BrahmerC. Butts, M. Steins, W. J. Geese, A. Li, D. Healey, L. Crinò

Research output: Contribution to journal › Article › peer-review

208 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases'. Together they form a unique fingerprint.

Medicine & Life Sciences